169 related articles for article (PubMed ID: 22145093)
1. Consequences of interrupted Rheb-to-AMPK feedback signaling in tuberous sclerosis complex and cancer.
Lacher MD; Pincheira RJ; Castro AF
Small GTPases; 2011 Jul; 2(4):211-216. PubMed ID: 22145093
[TBL] [Abstract][Full Text] [Related]
2. Rheb activates AMPK and reduces p27Kip1 levels in Tsc2-null cells via mTORC1-independent mechanisms: implications for cell proliferation and tumorigenesis.
Lacher MD; Pincheira R; Zhu Z; Camoretti-Mercado B; Matli M; Warren RS; Castro AF
Oncogene; 2010 Dec; 29(50):6543-56. PubMed ID: 20818424
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin requires AMPK activity and p27 expression for promoting autophagy-dependent Tsc2-null cell survival.
Campos T; Ziehe J; Fuentes-Villalobos F; Riquelme O; Peña D; Troncoso R; Lavandero S; Morin V; Pincheira R; Castro AF
Biochim Biophys Acta; 2016 Jun; 1863(6 Pt A):1200-7. PubMed ID: 26975583
[TBL] [Abstract][Full Text] [Related]
4. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.
Makovski V; Haklai R; Kloog Y
Int J Cancer; 2012 Mar; 130(6):1420-9. PubMed ID: 21500191
[TBL] [Abstract][Full Text] [Related]
5. Amino Acid-Mediated Intracellular Ca
Amemiya Y; Nakamura N; Ikeda N; Sugiyama R; Ishii C; Maki M; Shibata H; Takahara T
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34198993
[TBL] [Abstract][Full Text] [Related]
6. Tuberous sclerosis complex suppression in cerebellar development and medulloblastoma: separate regulation of mammalian target of rapamycin activity and p27 Kip1 localization.
Bhatia B; Northcott PA; Hambardzumyan D; Govindarajan B; Brat DJ; Arbiser JL; Holland EC; Taylor MD; Kenney AM
Cancer Res; 2009 Sep; 69(18):7224-34. PubMed ID: 19738049
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity.
Finlay GA; Malhowski AJ; Liu Y; Fanburg BL; Kwiatkowski DJ; Toksoz D
Cancer Res; 2007 Oct; 67(20):9878-86. PubMed ID: 17942919
[TBL] [Abstract][Full Text] [Related]
8. Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway.
Makovski V; Jacob-Hirsch J; Gefen-Dor C; Shai B; Ehrlich M; Rechavi G; Kloog Y
Cell Death Dis; 2014 Dec; 5(12):e1557. PubMed ID: 25476905
[TBL] [Abstract][Full Text] [Related]
9. Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase.
Avruch J; Hara K; Lin Y; Liu M; Long X; Ortiz-Vega S; Yonezawa K
Oncogene; 2006 Oct; 25(48):6361-72. PubMed ID: 17041622
[TBL] [Abstract][Full Text] [Related]
10. AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27.
Short JD; Houston KD; Dere R; Cai SL; Kim J; Johnson CL; Broaddus RR; Shen J; Miyamoto S; Tamanoi F; Kwiatkowski D; Mills GB; Walker CL
Cancer Res; 2008 Aug; 68(16):6496-506. PubMed ID: 18701472
[TBL] [Abstract][Full Text] [Related]
11. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.
Kwiatkowski DJ; Manning BD
Hum Mol Genet; 2005 Oct; 14 Spec No. 2():R251-8. PubMed ID: 16244323
[TBL] [Abstract][Full Text] [Related]
12. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.
Astrinidis A; Henske EP
Oncogene; 2005 Nov; 24(50):7475-81. PubMed ID: 16288294
[TBL] [Abstract][Full Text] [Related]
13. Phospholipase D1 is an effector of Rheb in the mTOR pathway.
Sun Y; Fang Y; Yoon MS; Zhang C; Roccio M; Zwartkruis FJ; Armstrong M; Brown HA; Chen J
Proc Natl Acad Sci U S A; 2008 Jun; 105(24):8286-91. PubMed ID: 18550814
[TBL] [Abstract][Full Text] [Related]
14. Blocking the Farnesyl Pocket of PDEδ Reduces Rheb-Dependent mTORC1 Activation and Survival of
Armijo ME; Escalona E; Peña D; Farias A; Morin V; Baumann M; Klebl BM; Pincheira R; Castro AF
Front Pharmacol; 2022; 13():912688. PubMed ID: 35814251
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of MAPK pathway is essential for suppressing Rheb-Y35N driven tumor growth.
Wang Y; Hong X; Wang J; Yin Y; Zhang Y; Zhou Y; Piao HL; Liang Z; Zhang L; Li G; Xu G; Kwiatkowski DJ; Liu Y
Oncogene; 2017 Feb; 36(6):756-765. PubMed ID: 27399332
[TBL] [Abstract][Full Text] [Related]
16. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.
Huang J; Wu S; Wu CL; Manning BD
Cancer Res; 2009 Aug; 69(15):6107-14. PubMed ID: 19602587
[TBL] [Abstract][Full Text] [Related]
17. Structural insights into TSC complex assembly and GAP activity on Rheb.
Yang H; Yu Z; Chen X; Li J; Li N; Cheng J; Gao N; Yuan HX; Ye D; Guan KL; Xu Y
Nat Commun; 2021 Jan; 12(1):339. PubMed ID: 33436626
[TBL] [Abstract][Full Text] [Related]
18. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
[TBL] [Abstract][Full Text] [Related]
19. The Neurodevelopmental Pathogenesis of Tuberous Sclerosis Complex (TSC).
Feliciano DM
Front Neuroanat; 2020; 14():39. PubMed ID: 32765227
[TBL] [Abstract][Full Text] [Related]
20. Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells.
Chen W; Pan Y; Wang S; Liu Y; Chen G; Zhou L; Ni W; Wang A; Lu Y
BMC Cancer; 2017 Jan; 17(1):34. PubMed ID: 28061838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
